Punwattie Ramnaraine
Payments from drug & device makers
Across 66 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$501
- Pfizer$99
- Lilly USA, LLC$91
- Biohaven Pharmaceutical Holding Company Ltd.$89
- Amgen$87
- GSK$59
- plus $356 from 14 others
What the payments were for
- Food & beverage$1,283100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $501 |
| Pfizer | 6 | $99 |
| Lilly USA, LLC | 6 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| Amgen | 5 | $87 |
| GSK | 3 | $59 |
| Abbott | 2 | $44 |
| Boston Scientific | 1 | $40 |
| Vifor Pharma, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Vertex | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$1,283 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $30,704 |
| RybelsusSemaglutide | 14 | $30,443 |
| MounjaroTirzepatide | 24 | $30,018 |
| JardianceEmpagliflozin | 21 | $28,844 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $27,422 |
| EliquisApixaban | 20 | $21,458 |
| TrulicityDulaglutide | 14 | $19,593 |
| XareltoRivaroxaban | 11 | $15,976 |
| JanuviaSitagliptin Phosphate | 13 | $10,799 |
| Novolog FlexpenInsulin Aspart | 24 | $5,356 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $2,534 |
| Atorvastatin Calcium | 212 | $1,930 |
| Ventolin HfaAlbuterol Sulfate | 33 | $1,918 |
| Gabapentin | 105 | $1,882 |
| Omeprazole | 85 | $1,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $19 | $61,14739 claims |
| Lilly USA, LLCMounjaro, Trulicity | $91 | $49,61138 claims |
| Boehringer IngelheimJardiance | $17 | $28,84421 claims |
| GSKTrelegy Ellipta | $59 | $27,42236 claims |
| PfizerEliquis | $99 | $21,45820 claims |
| Johnson & JohnsonXarelto | $33 | $15,97611 claims |
| AbbVieSynthroid | $501 | $60613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.
Other family in Ocala
- Kelly BowmanOcala$316K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.